Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ: APGE )

42.86 -2.18 (-4.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 472,460
Open 45.26
Bid (Size) 17.39 (1)
Ask (Size) 46.30 (4)
Prev. Close 45.04
Today's Range 42.85 - 46.37
52wk Range 16.39 - 72.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments 
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire

Performance

YTD
+50.33%
+50.33%
1 Month
-19.09%
-19.09%
3 Month
-11.35%
-11.35%
6 Month
-10.47%
-10.47%
1 Year
+144.08%
+144.08%

More News

Read More
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024
Via InvestorPlace
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
Via InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.